Literature DB >> 10856671

Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates.

K P Hunfeld1, P Kraiczy, T A Wichelhaus, V Schäfer, V Brade.   

Abstract

The spectrum of antibiotic susceptibility of Borrelia burgdorferi has been only partially defined. In the present study the effectiveness of 12 antimicrobials, belonging to six different antibiotic classes have been tested against Borrelia burgdorferi s.s. (N=3), Borrelia garinii (N=3), Borrelia afzelii (N=3), Borrelia valaisiana (N=1), and Borrelia bissettii (N=1) isolates. These isolates were analysed by a new standardised colorimetric minimal inhibitory concentration (MIC) method based upon colour changes that result from actively metabolizing spirochaetes after 72 h of incubation. Piperacillin (MIC90: 0.08 mg/l), ceftriaxone (MIC90: 0. 04 mg/l), cefotaxime (MIC90: 0.15 mg/l), azithromycin (MIC90: 0.015 mg/l), roxithromycin (MIC90: 0.05 mg/l) and quinupristin/dalfopristin (MIC90: 0.12 mg/l) gave the lowest MIC values. Minimal inhibibitory activity of amoxycillin (MIC90: 1.04 mg/l), cefixime (MIC90: 1.33 mg/l), cefoperazone (MIC90: 0.83 mg/l) tetracycline (MIC90: 0.29 mg/l) and minocycline (MIC90: 0.30 mg/l) was slightly lower, whereas borrelia were resistant to amikacin (MIC90: >128 mg/l). Mean minimal borreliacidal concentrations (MBCs) were representatively determined for piperacillin (MBC: 1.8 mg/l), ceftriaxone (MBC: 2.0 mg/l), azithromycin (MBC: 0.82 mg/ml), roxithromycin (MBC: 1.8 mg/l), quinupristin/dalfopristin (MBC: 5.0 mg/l), minocycline (MBC: 5.8 mg/l), and amikacin (MBC: >128 mg/l) by using conventional subculture for three weeks in combination with dark-field microscopy. B. garinii proved to be the most susceptible of the genospecies tested. Our study showed excellent in vitro antimicrobial activity of all classes of antibiotics tested, except the aminoglycosides and hence their suitability for therapy of Lyme disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10856671     DOI: 10.1016/s0924-8579(00)00116-3

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

1.  In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto.

Authors:  Martin Sicklinger; Ralf Wienecke; Uwe Neubert
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

2.  In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.

Authors:  P Kraiczy; J Weigand; T A Wichelhaus; P Heisig; H Backes; V Schäfer; G Acker; V Brade; K P Hunfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 3.  Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.

Authors:  Klaus-Peter Hunfeld; Volker Brade
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

4.  In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.

Authors:  Kristina Morgenstern; Georg Baljer; Douglas E Norris; Peter Kraiczy; Christa Hanssen-Hübner; Klaus-Peter Hunfeld
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

5.  In Vitro Susceptibility of the Relapsing-Fever Spirochete Borrelia miyamotoi to Antimicrobial Agents.

Authors:  Joris Koetsveld; Ronald O P Draga; Alex Wagemakers; Annemijn Manger; Anneke Oei; Caroline E Visser; Joppe W Hovius
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi.

Authors:  Klaus-Peter Hunfeld; Thomas A Wichelhaus; Rebecca Rödel; Georg Acker; Volker Brade; Peter Kraiczy
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

7.  Evaluation of the preventive capacities of a topically applied azithromycin formulation against Lyme borreliosis in a murine model.

Authors:  Jens Knauer; Inke Krupka; Christiane Fueldner; Joerg Lehmann; Reinhard K Straubinger
Journal:  J Antimicrob Chemother       Date:  2011-09-15       Impact factor: 5.790

8.  An RND-type efflux system in Borrelia burgdorferi is involved in virulence and resistance to antimicrobial compounds.

Authors:  Ignas Bunikis; Katrin Denker; Yngve Ostberg; Christian Andersen; Roland Benz; Sven Bergström
Journal:  PLoS Pathog       Date:  2008-02-29       Impact factor: 6.823

9.  In vitro susceptibility of Borrelia burgdorferi isolates to three antibiotics commonly used for treating equine Lyme disease.

Authors:  Sanjie Caol; Thomas Divers; Mark Crisman; Yung-Fu Chang
Journal:  BMC Vet Res       Date:  2017-09-29       Impact factor: 2.741

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.